Your browser doesn't support javascript.
COVID-19: gastrointestinal and hepatobiliary manifestations.
Shih, Angela R; Misdraji, Joseph.
  • Shih AR; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: ashih1@partners.org.
  • Misdraji J; Department of Pathology, Yale New Haven Hospital, Yale University, New Haven, CT, 06510, USA. Electronic address: joseph.misdraji@yale.edu.
Hum Pathol ; 2022 Jul 16.
Article in English | MEDLINE | ID: covidwho-2235561
ABSTRACT
SARS-CoV-2 is the viral agent of COVID-19, a pandemic that surfaced in 2019. Although predominantly a respiratory ailment, patients with COVID-19 can have gastrointestinal (GI) and hepatobiliary manifestations. These manifestations are often mild and transient, but they can be severe and consequential. In the GI tract, ischemic enterocolitis is the most common and significant consequence of COVID-19. In the liver, the reported pathologic findings may often be related to consequences of severe systemic viral infection, but reports of hepatitis presumed to be due to SARS-CoV-2 suggest that direct viral infection of the liver may be a rare complication of COVID-19. In both the GI tract and liver, lingering symptoms of GI or hepatic injury after resolution of pulmonary infection may be part of the evolving spectrum of long COVID.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Long Covid Language: English Journal subject: Pathology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Long Covid Language: English Journal subject: Pathology Year: 2022 Document Type: Article